Summary: The half-life of retatrutide is approximately 6 days, based on pharmacokinetic data from Phase 1 and Phase 2 clinical studies, which supports its once-weekly subcutaneous injection regimen
This, in turn, protects the liver from the harmful effects of toxic compounds and promotes their neutralization.Exposure to high levels of toxins exhausts glutathione faster than the body can produce or absorb from nutrition
Beyond glycaemic control, they slash cardiovascular risk by up to 26%, reduce the progression of kidney disease, and treat fatty liver and sleep apnoea, among others
Kidney and liver health, weight changes, activity level, and other medicines may also affect treatment decisions
Their review, however, found that most of the evidence of such health effects was from rodent studies , and only three small pilot studies had looked at BPC-157 use in humans
Biol Trace Element Res (1995) 49(2-3):8595